The Problem With “Just ADHD Testing” in Addiction Treatment

October 31, 2026

Why isolated symptom testing cannot carry a stimulant decision in a complex psychiatric or addiction presentation

A treatment-program administrator asked me about my rates for different kinds of testing, and the example offered to anchor the conversation was a familiar one. A psychiatrist wanted a client assessed for ADHD before feeling comfortable prescribing a stimulant, and the administrator assumed this would call for something narrower than a comprehensive evaluation. The phrase that carried the assumption was “just ADHD testing,” and the word doing the work in that phrase is “just.”

The question was a fair one, and a request for a focused service does not by itself establish that the psychiatrist intended to skip necessary clinical work. The problem lies in the language of referral, because “just ADHD testing” makes the required work sound much smaller than it is. In the complex mental health and addiction presentations I work with, the clinical task is to establish what explains the attention problems and what the evidence will support, and the wording of a referral settles neither question.

Stated directly, using isolated ADHD symptom testing as the sole basis for stimulant clearance, without assessing the broader clinical picture, is clinically inadequate and ethically indefensible. An ADHD diagnosis is an explanation of symptoms in the context of a person’s development, functioning, psychiatric history, and substance use, and a referral framed around medication does not remove the responsibility to supply that explanation. No evaluation clears a medication, since that decision belongs to the prescriber who writes it and monitors it. What an evaluation owes the prescriber is a supported account of what the evidence shows and where it stops.

That responsibility does not call for my full comprehensive evaluation in every case. The scope of any evaluation is set by what decision it is being asked to inform, what has already been established, what important uncertainty remains, and what further assessment would change the person’s care. A focused diagnostic evaluation can answer the developmental, differential, impairment, and risk questions adequately, and broader testing needs a clinical justification of its own. My answer to the administrator was to describe my own model rather than quote a service tier, and I do not offer an isolated symptom screen as medication authorization, whatever the referral calls it.

I use the term drive-by assessment for an assessment that reaches a diagnostic conclusion, or one a prescriber will treat as clearance, while omitting the history, differential diagnosis, and risk assessment needed to support it. The term describes omitted work, since test count, appointment length, and report length do not establish quality in either direction.

Attention complaints do not establish their cause

Two histories can produce an identical score on a symptom checklist while pointing in different directions, and that contrast is the clearest way I know to explain why the score cannot settle the question on its own. In one, teachers were describing distractibility and lost assignments years before substance use began, the difficulties held through sober stretches, and a parent confirms them without prompting. In the other, concentration was unremarkable through school, the complaints began alongside daily use in the early twenties, and the one informant who knew the person as a child remembers nothing of the kind. The first history provides substantially stronger support for an ADHD diagnosis, and the prescriber can weigh the medication question on that footing. The second leaves the diagnosis unresolved, directs attention to intoxication, withdrawal, mood, and sleep as competing explanations, and makes reassessment after stabilization part of the plan.

In the population I work with, attention difficulties sit alongside substance use, intoxication or withdrawal, trauma, mood symptoms, disrupted sleep, medication effects, and other psychiatric or cognitive concerns. Every one of those states can produce poor concentration, restlessness, impulsive decisions, and a trail of unfinished obligations, which is why the complaint alone tells me little about its source. A UK expert consensus on ADHD in substance use services makes the same point from the other direction, noting that ADHD symptoms overlap with intoxication and withdrawal states and that the two conditions produce similar outcomes, such as job loss and poor school performance [1].

The same consensus reports that a widely used adult ADHD self-report screen loses specificity in substance use populations and produces more false positives there than in the general population [1]. In the London detoxification study it cites, patients who screened positive for both childhood and current symptoms in the first days after admission were rescreened about a week later, once detoxified or stabilized [1, 7]. Of the 55 with repeat data, 22 no longer met the current-symptom threshold, a drop of 40 percent that the authors attribute to withdrawal states and the detoxification process [7]. The 33 who remained positive still needed a diagnostic interview, and among those who went on to one, about three in five received the diagnosis [7]. The consensus draws the practical conclusion that screening in addiction services should wait a few weeks rather than happen at admission, and that a positive screen should always be followed by a comprehensive clinical evaluation [1].

Timing matters for the same reason, and the consensus advises that clinical evaluations are best conducted during sustained abstinence or after detoxification and stabilization [1]. It acknowledges that this is hard to achieve in community settings and that abstinence is not a precondition for benefiting from ADHD medication [1]. An evaluation scheduled in the first days of an admission is therefore measuring a moving target, and the clinician who interprets it has to say so.

What the question needs is a timeline rather than a score, and building it is the center of the assessment. The timeline places childhood symptoms across settings, the onset and course of substance use, the emergence of psychiatric symptoms, and functioning during periods of greater stability in one sequence. The joint guideline of the American Society of Addiction Medicine and the American Academy of Addiction Psychiatry on stimulant use disorder frames the same discipline for prescribers [5]. It asks whether attentional problems follow the expected time course of stimulant-induced symptoms given the phase of use or whether they are present at other times as well. Several explanations can coexist in the same person, and a timeline is what lets a clinician weigh which of them the evidence supports.

The same process has to be able to find ADHD that has been overlooked, because the error runs in both directions. The consensus describes ADHD in addiction services as frequently missed, with symptoms and impairment attributed to substance use, and it warns against diagnostic overshadowing by practitioners who are not well versed in neurodevelopmental conditions [1]. Around 23 percent of people seeking treatment for a substance use disorder meet criteria for ADHD, and the stimulant use disorder guideline recommends that anyone using prescription stimulants nonmedically be evaluated for it [1, 5]. When a thorough assessment identifies ADHD it should open the way to treatment instead of delaying it. The guideline endorses treating ADHD within stimulant use disorder care, with stimulant medication when the benefits outweigh the risks, and the UK consensus calls treatment nihilism toward this group inappropriate [1, 5].

The work behind a supported conclusion

A supported conclusion rests on a set of ordinary clinical activities, and the first is developmental interviewing. That means eliciting concrete examples of how attention, activity level, and self-regulation operated in childhood classrooms, friendships, and family life, and how those same capacities operate now at work and at home. The UK quality standard for adult ADHD assessment describes this as a detailed explorative interview with open questions and probing for real-life examples, and it warns that a checklist of closed questions invites confirmation bias and can miss important differential diagnoses [2].

The second is a review of whatever records exist, because school records, prior evaluations, treatment summaries, and prescription histories anchor a timeline that memory alone cannot. Retrospective recall is fallible in everyone, and the consensus notes that the cognitive effects of a substance use disorder can compromise it further [1]. A note from a third-grade teacher describing a child who could not stay in his seat is a different kind of evidence from an adult’s recollection of the same thing, and the report should say which kind each one is.

The third is collateral information gathered with the person’s consent, ideally from someone who knew them as a child and from someone who knows their current daily functioning, which is the pairing the quality standard recommends [2]. Informants disagree with patients and with each other, and reconciling those accounts is clinical work, because the pattern of disagreement is itself informative. A parent who recalls a placid child and a partner who describes a chaotic adult are telling me something. The work is to determine whether it concerns onset or how much a quiet child’s inattention went unnoticed, since the consensus notes that compensatory strategies can mask symptoms [1].

The fourth is a systematic assessment of symptoms and impairment, with impairment documented across settings and at a level that reduces the quality of functioning, because a trait that is merely noticeable does not meet that bar. The fifth is differential diagnosis, which is the component most easily sacrificed when a referral is framed narrowly. The requirement that symptoms are not better explained by another condition is written into the diagnostic criteria themselves, and skipping it leaves a criterion unassessed [2]. The sixth is risk assessment, which the quality standard treats as essential in every assessment and which widens when medication is in view [2]. That review covers comorbidity, cardiovascular status, substance misuse, and the potential for misuse or diversion of the medication being considered.

Records and informants are not always available, and the consensus is explicit that missing collateral information should not delay or prevent an assessment [1]. Whether their absence changes the conclusion depends on the case, since the remaining evidence is sometimes sufficient and sometimes leaves confidence materially limited. The psychologist’s obligations are the same either way, because an opinion must rest on information sufficient to substantiate it and any significant limitation on the interpretation has to be stated [3]. That is the difference between a focused evaluation and a drive-by, since the focused evaluation says plainly what it could not establish while the other presents the gap as if it were closed.

Testing enters this process in service of specific questions that the history has raised, and every instrument I administer needs a purpose I can state. In neuropsychological assessment the first question is whether the data can be interpreted, which is why validity assessment is routine rather than reserved for examinees who raise suspicion [8]. Performance validity informs the interpretability of cognitive performance, and symptom validity informs the credibility of symptom reporting. A failed indicator limits what the data can support, and on its own it establishes nothing about intent [8]. The consensus notes that a small number of people seek ADHD assessment in order to obtain stimulant medication, and it advises clinicians to ask about expectations and to bear in mind that symptoms can be exaggerated for external gain [1]. Academic measures address a learning problem that may be masquerading as inattention, and cognitive and executive measures can characterize how a person’s mind works and what the team will need to accommodate. What none of them can do is diagnose ADHD on their own, since no cognitive, imaging, or biological test currently has the sensitivity and specificity to do so [2].

None of this is measured by volume, and the quality standard makes the point explicitly. It acknowledges that report length is no marker of quality while insisting that the relevant information still be present in sufficient detail [2]. The same standard recommends at least two hours of direct contact in most cases, a figure that includes feedback and the initial discussion of treatment, with shorter times possible in simpler cases and longer ones expected as complexity rises [2]. The presentations in addiction treatment are rarely simple, which places most of them at the longer end of that range.

The population in front of us

The person in front of me may be weeks out of detoxification with sleep that has not normalized. There may be a trauma history that no one has explored in detail and a medication regimen that changed twice during the last admission. The attention problems that person describes may predate all of it or none of it, and the only way to know is to ask the questions that would distinguish the two. The stimulant use disorder guideline builds those questions into its own comprehensive assessment, which pairs a mental status examination that looks for ADHD, mood disorders, psychosis, cognitive impairment, and risk of harm with a full biopsychosocial assessment [5]. When a program has done that work, my evaluation begins by reviewing it and judging whether it answers the ADHD question, in coordination with the team, and then fills the gaps that matter. Work that has already been done adequately does not need repeating, and the four scope questions above decide what follows.

Instability is the other half of the difficulty, since the consensus estimates that a substance use disorder can amplify ADHD symptoms by as much as 30 percent [1]. That exacerbation may lessen with successful treatment of the substance use, which is the case for reassessment. A formulation written for this population therefore carries a date on it. Part of its usefulness to the treating team is stating which findings are likely to hold and which should be revisited once sleep, mood, and sobriety have settled.

Stimulant use in sexual contexts, including the pattern often called chemsex, belongs in this history when it is relevant, as a pattern and context of use rather than as a moral category. The stimulant use disorder guideline directs clinicians to assess risky sexual behavior and recommends asking about the context of stimulant use [5]. It names chemsex alongside weight loss, academic or work performance, and staying awake, and it places trauma and intimate partner violence in the same set of questions. None of that carries assumptions about who the person is, and all of it is entered alongside the rest of the substance history and the associated psychiatric and health concerns. A stimulant prescribed into a life where stimulants are already tied to sex, sleeplessness, or performance meets different risks than the same prescription written for someone with no such history. The prescriber deserves to know which situation applies before the first prescription is written [4, 5].

Why psychiatrists ask for an integrated formulation

In my own clinical conversations, a psychiatrist has described seeking assessments because of concern about prescribing liability, and I take that as a reasonable professional position. A 2016 risk-management publication for psychiatrists lists the allegations typically raised in psychopharmacology claims, and the first category is negligence in prescribing [6]. That category concerns the adequacy of the assessment or evaluation of the patient, the diagnostic formulation, and the decisions about which medication to prescribe and how. The remaining categories concern the administration of medication, its monitoring, and informed consent. The same publication advises collecting information about the patient from the patient, from family members and significant others as appropriate, and from other providers, including past treatment records [6].

Federal drug safety guidance points the same way, since the FDA’s 2023 update to the class-wide stimulant warnings directs prescribers to assess each patient’s risk of misuse, abuse, and addiction before prescribing [4]. It also directs them to monitor for nonmedical use and diversion throughout treatment. That guidance does not require neuropsychological testing before every stimulant prescription, and I would not argue that it should. What the risk assessment requires is information adequate to the presentation, and in a complex presentation that information is substantial.

What a psychiatrist in that position needs from me is a document that shows its evidence and explains the competing diagnoses and why each was retained or set aside. It identifies the risks that bear on prescribing and makes recommendations the evidence supports. The formulation also feeds decisions that remain the psychiatrist’s alone, since the stimulant use disorder guideline asks prescribers treating ADHD in this population to consider extended-release formulations [5]. It also asks them to maintain a level of monitoring matched to the risk profile of the medication and the patient. A report that has already characterized that risk profile makes those choices better informed, and a report that has not leaves the prescriber to reconstruct it from a clearance letter.

The division of accountability is clear, and I would not blur it, because I am accountable for the assessment and its conclusions and the psychiatrist is accountable for prescribing and monitoring. Collaboration of that kind gives each clinician better information for a decision that remains their own. The risk-management literature treats consultation itself as a protective practice that demonstrates thoughtful decision-making [6].

The ethics are about adequacy

The ethical concern is not complicated, because it concerns the issuance of a consequential conclusion without information sufficient to support it. The American Psychological Association’s ethics code requires that opinions in reports and diagnostic statements rest on information and techniques sufficient to substantiate them [3]. It requires that assessment methods be used for purposes the evidence supports, and that interpretation account for the characteristics of the person and the purpose of the assessment while stating any significant limitations. A conclusion that a prescriber will rely on is among the most consequential statements a report can carry, and the standards do not relax because the referral was phrased narrowly.

Screening has a legitimate role, and the limited screening service I had proposed to the program was designed for it, to help a clinical team identify treatment-planning needs across many clients and to support ongoing collaboration with the staff. A positive screen identifies a need for further assessment, which is a useful thing to know in a program managing many clients at once. It cannot supply the developmental history or weigh the competing causes, and it cannot by itself establish whether a stimulant is suitable for this person. The UK quality standard would keep self-completed symptom scales to a baseline for tracking change after diagnosis, while the UK national guideline treats rating scales as useful additions that cannot carry a diagnosis on their own [2, 9]. Either position leaves the same work to the clinician, since a scale contributes evidence and cannot carry the conclusion.

After the scores

In my practice the work continues well past the scoring, through interpretation, the written formulation, feedback to the person and to the family where appropriate, and collaboration with the treating team. When school or workplace accommodations are in question, assessment-related documentation follows within the agreed scope, and an accommodation letter built on a screen inherits every weakness of the screen, as a prescription does. The clinical value of an evaluation lies in connecting its findings to the person’s care, which is where a conclusion is tested against the treatment it was meant to inform.

I conduct this work myself, without psychological assistants, and a complex comprehensive case takes approximately thirty-five hours of my time. Those hours go to the interviews, the records, the collateral contacts, the testing, the integration, the written report, the separate client-facing feedback materials, and the coordination with the treating team. I limit the number of comprehensive cases I take at once so that findings arrive while treatment is still underway and can still change it. The hours describe my model for a complex comprehensive case rather than the workload every adequate ADHD evaluation requires. A long evaluation can be as unsupported as a short one when the time is spent on the wrong things.

The expectation

The professional expectation I would ask every reader to hold is that the assessment must support the conclusion and the treatment decisions it is being asked to inform. That applies whether the reader refers, prescribes, runs a program, or sits in the waiting room. In practice it means that a usable evaluation shows the evidence behind the diagnosis and names the competing explanations and how they were weighed. It documents the impairment, identifies the risks that bear on prescribing, states what remains uncertain, and says what the findings mean for care. A request for “just ADHD testing” deserves that answer in full rather than a smaller version of it. When the work cannot be done, the honest answer names what the evaluation could not establish. When it can be done, the conclusion will hold the weight that a stimulant prescription in a complex presentation places on it.

The referral exchange described here is drawn from practice and has been generalized. No patient, clinician, or program is identified, and no evaluation, prescribing decision, or outcome is described.

References

[1]  Young, S., Abbasian, C., Al-Attar, Z., Branney, P., Colley, B., Cortese, S., Cubbin, S., Deeley, Q., Gudjonsson, G. H., Hill, P., Hollingdale, J., Jenden, S., Johnson, J., Judge, D., Lewis, A., Mason, P., Mukherjee, R., Nutt, D., Roberts, J., Robinson, F., Woodhouse, E., & Cocallis, K. (2023). Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement. World Journal of Psychiatry, 13(3), 84–112. https://doi.org/10.5498/wjp.v13.i3.84

[2]  Adamou, M., Arif, M., Asherson, P., Cubbin, S., Leaver, L., Sedgwick-Müller, J., Müller-Sedgwick, U., van Rensburg, K., & Kustow, J. (2024). The adult ADHD assessment quality assurance standard. Frontiers in Psychiatry, 15, 1380410. https://doi.org/10.3389/fpsyt.2024.1380410

[3]  American Psychological Association. (2017). Ethical principles of psychologists and code of conduct (2002, amended effective June 1, 2010, and January 1, 2017), Standards 9.01, 9.02, and 9.06. https://www.apa.org/ethics/code

[4]  U.S. Food and Drug Administration. (2023, May 26). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions (MedWatch safety communication summarizing the May 11, 2023 Drug Safety Communication). https://www.fda.gov/safety/medical-product-safety-information/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions

[5]  American Society of Addiction Medicine & American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine, 18(1S), 1–56. https://doi.org/10.1097/ADM.0000000000001299 (Recommendations 2, 24, 26, 27, 77, and 78.) https://pmc.ncbi.nlm.nih.gov/articles/PMC11105801/

[6]  Professional Risk Management Services. (2016). Risk management and psychopharmacology: Allegations of negligence related to psychopharmacology. Rx for Risk, 24(1), 3–8. https://www.prms.com/media/1664/rx_for_risk_v24_issue1_digital.pdf

[7]  Huntley, Z., Maltezos, S., Williams, C., Morinan, A., Hammon, A., Ball, D., Marshall, E. J., Keaney, F., Young, S., Bolton, P., Glaser, K., Howe-Forbes, R., Kuntsi, J., Xenitidis, K., Murphy, D., & Asherson, P. J. (2012). Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units. BMC Psychiatry, 12, 223. https://doi.org/10.1186/1471-244X-12-223

[8]  Sweet, J. J., Heilbronner, R. L., Morgan, J. E., Larrabee, G. J., Rohling, M. L., Boone, K. B., Kirkwood, M. W., Schroeder, R. W., Suhr, J. A., & Conference Participants. (2021). American Academy of Clinical Neuropsychology (AACN) 2021 consensus statement on validity assessment: Update of the 2009 AACN consensus conference statement on neuropsychological assessment of effort, response bias, and malingering. The Clinical Neuropsychologist, 35(6), 1053–1106. https://doi.org/10.1080/13854046.2021.1896036

[9]  National Institute for Health and Care Excellence. (2018, updated 2019). Attention deficit hyperactivity disorder: Diagnosis and management (NICE guideline NG87), Recommendation 1.3.2. https://www.nice.org.uk/guidance/ng87

You Might Also Like